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Small-cell lung cancer (SCLC) is a disease for which there has been no advance in sys-temic therapy for the past 30 years. In the background of this sobering data are many 
attempts to find targeted therapy that can have a real impact on patient outcome.1 These 
attempts may have failed largely because of our inability to identify subgroups of SCLC 
patients who have an appropriate predictive biomarker for response. Thus, in this setting, 
investigators are attempting to define, similar to non–small-cell lung cancer (NSCLC), 
subgroups of SCLC which behave differently. This represents a departure from what has 
traditionally been viewed as a homogeneous disease. An obvious subgroup, representing 
approximately 1% of all SCLC, are patients with so-called “peripheral SCLC” which pres-
ent with a solitary pulmonary nodule and whom are candidates for surgery.2 Most genomic 
data published to date have focused on this group,3,4 which has a very different clinical 
course than the classic SCLC we observe in everyday clinical practice. Another subgroup is 
the so-called “combined SCLC,” previously called “mixed SCLC,” which has histological 
features of both SCLC and NSCLC and may also behave differently.5 This entity represents 
a fascinating disease because it puts into question the cellular origin of SCLC, which is an 
area of active investigation.6,7
With this knowledge, Varghese et al. are identifying yet another rare subgroup, 
SCLC patients who have never smoked. In our clinical practice, we have only seen three 
 never-smoker patients with SCLC, and without epidermal growth factor receptor (EGFR) 
mutations, among 420 patients (0.7%) who are part of our ongoing clinicopathological 
SCLC database. Interest in this subgroup has mainly arisen from the observations that 
EGFR-mutant NSCLC patients treated with EGFR kinase inhibitors may transform into 
SCLC as a mechanism of resistance.8 Because we are now routinely performing repeat 
biopsies on patients with EGFR mutation disease, this transformation is being seen on a 
much more common basis (3 patients in the past 4 months in our clinical practice alone). 
These patients seem to be somewhat more resistant to SCLC-directed therapy with initial 
impressions of lower response rates and shorter time to progression.
Multiple explanations for the occurrence of SCLC in never-smokers may be evoked. 
One explanation may simply be that it represents “an extrapulmonary SCLC,” which may 
occur in people who have never smoked and can arise in various organs, including the gas-
trointestinal and genitourinary systems, but just happens to occur in the lung.9 The causative 
factor for extrapulmonary SCLC remains unknown. Another putative explanation may be 
that SCLC of never-smokers may simply represent a dedifferentiation of a previously well-
differentiated cancer, similar to what may be seen in prostate cancer transformation into 
small-cell variety after prolonged androgen ablation.10 Indeed, we observed a case of NSCLC 
transforming into SCLC without EGFR tyrosine kinase inhibitor therapy. Another plausible 
explanation may be that we are really dealing with a “combined SCLC,” but because of a 
paucity of biopsy material, only the SCLC part is being seen.5 Yet another explanation is 
that the observed SCLC in the chest of a never-smoker may be a so-called “Askin tumor,” a 
primitive neuroectodermal tumor of the Ewing family tumors. Although these are generally 
seen in children, adults can also be afflicted.11 These rare, small, blue cell tumors can be 
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/14/0906-0750
Defining Subgroups of Small-Cell Lung Cancer
Afshin Dowlati, MD, and Gary Wildey, PhD
Division of  Hematology and Oncology, Case Western Reserve University and University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer 
Center, Cleveland, Ohio.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Afshin Dowlati, MD, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106. E-mail: afshin.dowlati@case.edu
XXX
EDITORIAL
751Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 6, June 2014 Defining Subgroups of SCLC
diagnosed as SCLC in the adult population. We have recently 
seen a case in a 70-year-old light-smoker female who pre-
sented with SCLC. After sequencing the tumor, we discovered 
the classic fusion oncogene for Ewing’s sarcoma, translocation 
of the Ewing sarcoma (EWS) gene on chromosome 22 to the 
Fli-1 proto-oncogene (FLI1) gene on chromosome 11, indicat-
ing most likely a tumor from the Ewing family. It is unclear 
whether this translocation was part of the mutation panel used 
in the study by Varghese et al. Finally, a simple explanation 
may be related to the use of self-administered smoking history 
questionnaires, which have always been criticized.
The study by Varghese et al. also highlights the diffi-
culties in obtaining tissue from SCLC patients for genomic 
analyses. Indeed, in their series, only two patients had enough 
tissue for targeted next-generation sequencing. The group 
at Memorial Sloan Kettering Cancer Center should be com-
mended for their persistent efforts to further define and under-
stand a disease for which therapeutic progress is long overdue.
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